Robert J. Alpern - 30 Sep 2025 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role: Director
Signature: /s/ T.O. Odutayo, Attorney-in-Fact for Robert J. Alpern
Issuer symbol: ABBV
Transactions as of: 30 Sep 2025
Net transactions value: +$7,641
Form type: 4
Filing time: 02 Oct 2025, 17:00:17 UTC
Previous filing: 01 Jul 2025
Next filing: 05 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Alpern Robert J	Director	1 N. WAUKEGAN ROAD, NORTH CHICAGO	/s/ T.O. Odutayo, Attorney-in-Fact for Robert J. Alpern	02 Oct 2025	0001448074

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABBV	Stock Equivalent Units	Award	$7,641	+33	+0.33%	$231.54	10,151	30 Sep 2025	Common Stock	33	$231.54	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
F2	Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Content

Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.